M6A RNA Methylation Regulates Histone Ubiquitination to Support Cancer Growth and Progression.


Journal

Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R

Informations de publication

Date de publication:
16 05 2022
Historique:
received: 02 07 2021
revised: 04 02 2022
accepted: 16 03 2022
pubmed: 19 3 2022
medline: 20 5 2022
entrez: 18 3 2022
Statut: ppublish

Résumé

Osteosarcoma is the most common malignancy of the bone, yet the survival for patients with osteosarcoma is virtually unchanged over the past 30 years. This is principally because development of new therapies is hampered by a lack of recurrent mutations that can be targeted in osteosarcoma. Here, we report that epigenetic changes via mRNA methylation holds great promise to better understand the mechanisms of osteosarcoma growth and to develop targeted therapeutics. In patients with osteosarcoma, the RNA demethylase ALKBH5 was amplified and higher expression correlated with copy-number changes. ALKBH5 was critical for promoting osteosarcoma growth and metastasis, yet it was dispensable for normal cell survival. Methyl RNA immunoprecipitation sequencing analysis and functional studies showed that ALKBH5 mediates its protumorigenic function by regulating m6A levels of histone deubiquitinase USP22 and the ubiquitin ligase RNF40. ALKBH5-mediated m6A deficiency in osteosarcoma led to increased expression of USP22 and RNF40 that resulted in inhibition of histone H2A monoubiquitination and induction of key protumorigenic genes, consequently driving unchecked cell-cycle progression, incessant replication, and DNA repair. RNF40, which is historically known to ubiquitinate H2B, inhibited H2A ubiquitination in cancer by interacting with and affecting the stability of DDB1-CUL4-based ubiquitin E3 ligase complex. Taken together, this study directly links increased activity of ALKBH5 with dysregulation of USP22/RNF40 and histone ubiquitination in cancers. More broadly, these results suggest that m6A RNA methylation works in concert with other epigenetic mechanisms to control cancer growth. RNA demethylase ALKBH5 upregulates USP22 and RNF40 to inhibit histone H2A ubiquitination and induces expression of key replication and DNA repair-associated genes, driving osteosarcoma progression.

Identifiants

pubmed: 35303054
pii: 682272
doi: 10.1158/0008-5472.CAN-21-2106
pmc: PMC9336196
mid: NIHMS1821831
doi:

Substances chimiques

Histones 0
Ubiquitins 0
RNA 63231-63-0
AlkB Homolog 5, RNA Demethylase EC 1.14.11.-
Ubiquitin Thiolesterase EC 3.4.19.12
Usp22 protein, human EC 3.4.19.12

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1872-1889

Subventions

Organisme : NCI NIH HHS
ID : R01 CA179120
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA165995
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA239227
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA205224
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA148724
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA054174
Pays : United States

Informations de copyright

©2022 American Association for Cancer Research.

Références

DNA Repair (Amst). 2015 Dec;36:36-42
pubmed: 26422137
Cell Discov. 2015;1:
pubmed: 27030811
Onco Targets Ther. 2018 May 23;11:3035-3046
pubmed: 29872315
Cancer Cell Int. 2020 Jan 30;20:34
pubmed: 32021563
Nat Commun. 2018 Mar 8;9(1):1006
pubmed: 29520062
Nat Commun. 2016 Aug 25;7:12648
pubmed: 27557628
DNA Repair (Amst). 2017 Aug;56:92-101
pubmed: 28624371
Cell Res. 2017 Mar;27(3):444-447
pubmed: 28106076
BMC Cancer. 2016 Mar 15;16:223
pubmed: 26979530
Bioinformatics. 2013 Jun 15;29(12):1565-7
pubmed: 23589649
Front Genet. 2015 Sep 08;6:282
pubmed: 26442100
Mol Cell. 2020 Feb 20;77(4):840-856.e5
pubmed: 31883952
PLoS One. 2012;7(12):e52397
pubmed: 23285024
Biomed Res Int. 2016;2016:8367534
pubmed: 27239475
Mol Cell Biol. 2006 Nov;26(21):7977-90
pubmed: 16940174
Nature. 2017 Dec 7;552(7683):126-131
pubmed: 29186125
Cell Death Differ. 2017 Apr;24(4):694-704
pubmed: 28157208
Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2588-93
pubmed: 16473935
Int J Cancer. 2020 Sep 15;147(6):1528-1534
pubmed: 32010971
Cancer Res. 2002 Nov 15;62(22):6414-7
pubmed: 12438226
Cell. 2015 Jun 4;161(6):1388-99
pubmed: 26046440
Genes Dev. 2006 May 15;20(10):1343-52
pubmed: 16702407
Proc Natl Acad Sci U S A. 2018 Oct 2;115(40):E9298-E9307
pubmed: 30224477
Front Oncol. 2012 Mar 12;2:26
pubmed: 22649782
J Cell Physiol. 2017 Dec;232(12):3664-3676
pubmed: 28160502
J Clin Invest. 2005 Jun;115(6):1503-21
pubmed: 15931389
Nat Rev Cancer. 2014 Nov;14(11):722-35
pubmed: 25319867
Curr Opin Struct Biol. 2017 Dec;47:67-76
pubmed: 28624569
Mol Cell. 2008 Jan 18;29(1):102-11
pubmed: 18206973
IEEE/ACM Trans Comput Biol Bioinform. 2018 Mar-Apr;15(2):526-534
pubmed: 29610101
Mol Cell Endocrinol. 2012 Mar 5;350(1):87-98
pubmed: 22155569
Cell Res. 2014 Feb;24(2):177-89
pubmed: 24407421
Nature. 2019 Feb;566(7743):270-274
pubmed: 30728504
Cell. 2013 Nov 7;155(4):793-806
pubmed: 24209618
Nat Rev Cancer. 2011 Feb;11(2):96-110
pubmed: 21258395
Cell Death Dis. 2021 Jan 11;12(1):60
pubmed: 33431791
Cell Rep. 2014 Jul 10;8(1):284-96
pubmed: 24981863
Nucleic Acids Res. 2021 Jan 8;49(D1):D1321-D1327
pubmed: 32810235
Mol Cancer Res. 2020 Mar;18(3):424-435
pubmed: 31685642
Sci Adv. 2018 Oct 03;4(10):eaar8263
pubmed: 30306128
Cancer Metastasis Rev. 2014 Dec;33(4):981-91
pubmed: 25315817
Int J Biochem Cell Biol. 2009 Jan;41(1):12-5
pubmed: 18929679
FEBS Lett. 2011 Sep 16;585(18):2795-802
pubmed: 21827756
Nat Chem Biol. 2011 Oct 16;7(12):885-7
pubmed: 22002720
Cancer Cell. 2017 Apr 10;31(4):591-606.e6
pubmed: 28344040
Biosci Rep. 2020 Apr 30;40(4):
pubmed: 32266933
Int J Clin Exp Pathol. 2018 May 01;11(5):2901-2906
pubmed: 31938414
Oncol Rep. 2014 Oct;32(4):1451-8
pubmed: 25070659
Cell Stem Cell. 2014 Dec 4;15(6):707-19
pubmed: 25456834
Mol Cell. 2007 Aug 17;27(4):609-21
pubmed: 17707232
Oncotarget. 2016 Jul 12;7(28):44848-44856
pubmed: 27057639
Mol Cell. 2013 Jan 10;49(1):18-29
pubmed: 23177736
Cell Cycle. 2008 Jun 1;7(11):1522-4
pubmed: 18469533
Cancer Res. 2020 Feb 1;80(3):430-443
pubmed: 31740444
Mol Cell Biol. 2019 Apr 2;39(8):
pubmed: 30692271
Proc Natl Acad Sci U S A. 2016 Apr 5;113(14):E2047-56
pubmed: 27001847
Cancer Res. 2008 Jul 1;68(13):5014-22
pubmed: 18593899
Int J Cancer. 2009 Jul 1;125(1):229-34
pubmed: 19330840
Mol Cell. 2008 Jan 18;29(1):69-80
pubmed: 18206970
Cell Rep. 2016 May 17;15(7):1554-1565
pubmed: 27160905
Nature. 2014 Jan 2;505(7481):117-20
pubmed: 24284625
Biochem Biophys Res Commun. 2019 Aug 27;516(3):719-725
pubmed: 31253399
Bio Protoc. 2017 Jan 05;7(1):e2095
pubmed: 34458425
Mol Cell Biol. 2000 Oct;20(20):7751-63
pubmed: 11003670

Auteurs

Pooja Yadav (P)

Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, Texas.
Department of Cell Systems and Anatomy, University of Texas Health Science Center at San Antonio, San Antonio, Texas.

Panneerdoss Subbarayalu (P)

Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, Texas.
Department of Cell Systems and Anatomy, University of Texas Health Science Center at San Antonio, San Antonio, Texas.

Daisy Medina (D)

Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, Texas.
Department of Cell Systems and Anatomy, University of Texas Health Science Center at San Antonio, San Antonio, Texas.

Saif Nirzhor (S)

Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, Texas.
Department of Cell Systems and Anatomy, University of Texas Health Science Center at San Antonio, San Antonio, Texas.

Santosh Timilsina (S)

Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, Texas.
Department of Cell Systems and Anatomy, University of Texas Health Science Center at San Antonio, San Antonio, Texas.

Subapriya Rajamanickam (S)

Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, Texas.
Department of Molecular Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas.

Vijay K Eedunuri (VK)

Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, Texas.

Yogesh Gupta (Y)

Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, Texas.
Department of Biochemistry, University of Texas Health Science Center at San Antonio, San Antonio, Texas.

Siyuan Zheng (S)

Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, Texas.

Nourhan Abdelfattah (N)

Houston Methodist Research Institute, Houston, Texas.

Yufei Huang (Y)

Department of Electrical and Computer Engineering, University of Texas at San Antonio, San Antonio, Texas.

Ratna Vadlamudi (R)

Department of Obstetrics and Gynecology, University of Texas Health Science Center at San Antonio, San Antonio, Texas.

Robert Hromas (R)

Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas.

Paul Meltzer (P)

Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.

Peter Houghton (P)

Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, Texas.
Department of Molecular Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas.

Yidong Chen (Y)

Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, Texas.
Department of Epidemiology and Biostatistics, University of Texas Health Science Center at San Antonio, San Antonio, Texas.

Manjeet K Rao (MK)

Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, Texas.
Department of Cell Systems and Anatomy, University of Texas Health Science Center at San Antonio, San Antonio, Texas.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH